TRVIHIGH SIGNALFINANCIAL10-K

TRVI experienced dramatic balance sheet strengthening with stockholders' equity surging 84% to $183M, but concerning cash burn accelerated to $42M while cash reserves declined 45%.

The massive equity increase suggests significant external funding or favorable warrant exercises, providing substantial capital to advance Haduvio development. However, the accelerating cash burn rate combined with declining cash reserves creates a concerning trajectory that could pressure future funding needs despite the current strong balance sheet position.

Comparing 2026-03-17 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

TRVI's financial profile shows a tale of two narratives - exceptional balance sheet strengthening with stockholders' equity jumping 84% to $183M and total assets growing 74% to $193M, indicating successful capital raising activities. However, operational metrics reveal concerning trends with cash reserves declining 45% to $19M while operating cash outflows increased 10% to $42M annually, creating potential liquidity pressures. Despite reduced R&D spending and improved net losses, the accelerating cash burn against a shrinking cash base suggests the company may need additional financing within the next 12-18 months to sustain operations.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+83.9%
$99.6M$183.2M

Equity base grew 83.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+75.1%
$109.4M$191.7M

Current assets grew 75.1% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+74.4%
$110.9M$193.4M

Asset base grew 74.4% — expansion through organic growth, acquisitions, or capital deployment.

Interest Expense
P&L
-66.4%
$1.2M$391K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Capital Expenditure
Cash Flow
-65.7%
$35K$12K

Capex reduced 65.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-44.5%
$34.1M$18.9M

Cash declined 44.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

R&D Expense
P&L
-15%
$39.4M$33.5M

R&D spending cut 15% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
+10.8%
-$47.9M-$42.8M

Net income grew 10.8% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
-10%
-$38.3M-$42.1M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-03-18
ADDED
For instance, Haduvio may fail to show the desired safety and efficacy results in our planned trials of Haduvio despite demonstrating positive results in earlier Phase 2 clinical trials.
Exhibits, Financial Statement Schedules 93 Item 16 Form 10-K Summary 95 PART I Item 1.
Haduvio acts on the cough reflex arc both centrally and peripherally as a k appa receptor a gonist and a m u receptor a ntagonist ( KAMA ), targeting opioid receptors that play a key role in controlling chronic cough.
Nalbuphine has been approved and marketed as an injectable for pain indications for decades in the United States, or the U.S., and Europe.
Parenteral nalbuphine is not scheduled as a controlled substance by the U.S.
+7 more — sign up free →
REMOVED
For instance, Haduvio may fail to show the desired safety and efficacy in clinical development despite demonstrating positive results in earlier clinical trials.
Exhibits, Financial Statement Schedules 92 Item 16 Form 10-K Summary 94 PART I Item 1.
Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist, or KAMA.
Kappa and mu are opioid receptors that play a key role in controlling cough hypersensitivity.
Nalbuphine has been approved and marketed as an injectable for pain indications for more than 30 years in the United States, or the U.S., and Europe.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →